drugset
drugset / Trial / NCT01582815

A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms

NCT01582815 ↗

Phase 2 Completed 121 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and overall safety and tolerability of treatment with adjunctive JNJ-40411813 compared to placebo in patients with MDD with anxiety symptoms being treated with an antidepressant.

Timeline

Start
2012-09
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-40411813 Small molecule 25 mg Oral
Subject JNJ-40411813 Small molecule 150 mg Oral

Indications

major depressive disorder